<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="236904">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004992</url>
  </required_header>
  <id_info>
    <org_study_id>(IND) - DPP (completed)</org_study_id>
    <secondary_id>DK48489</secondary_id>
    <nct_id>NCT00004992</nct_id>
  </id_info>
  <brief_title>Diabetes Prevention Program</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <brief_summary>
    <textblock>
      The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can
      Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or
      delayed? The study has recruited 3819 volunteers, who are at high risk of developing
      diabetes, at twenty-five medical centers in the United States. It is sponsored by the
      National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes
      of Health, and other Institute and corporate sponsors. Researchers will evaluate the
      efficacy of a lifestyle intervention and a pharmacological intervention in preventing or
      delaying Type 2 diabetes in persons with IGT, impaired glucose tolerance. Each person in the
      study will be followed for 3 to 6 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date>April 2001</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <enrollment>3819</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Glucose Intolerance</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive lifestyle</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance (FPG 95-125 mg/dL and 2hr PG 140-199 mg/dL)

          -  BMI &gt;= 24 kg/m2

        Exclusion Criteria:

          -  Underlying disease likely to limit life span and/or increase risk of interventions

          -  Conditions or behaviors likely to effect conduct of the DPP

          -  Diabetes or disordered glucose metabolism

          -  Suboptimally treated Thyroid disease

          -  Fasting triglyceride level &lt; 600 mg/dl

          -  Exclusions related to medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Fowler, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Biostatistics Center, Suite 750, 6110 Executive Blvd</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.preventdiabetes.com</url>
    <description>The web site of the Diabetes Prevention Program (DPP)</description>
  </link>
  <results_reference>
    <citation>Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group.. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20;355(3):241-50.</citation>
    <PMID>16855264</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 3, 2011</lastchanged_date>
  <firstreceived_date>March 17, 2000</firstreceived_date>
  <keyword>clinical trial</keyword>
  <keyword>multi-center</keyword>
  <keyword>NIDDM</keyword>
  <keyword>NIDDK</keyword>
  <keyword>DPP</keyword>
  <keyword>diabetes risk factors</keyword>
  <keyword>diabetes</keyword>
  <keyword>glycemia</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>quality of life</keyword>
  <keyword>physical activity and nutrition</keyword>
  <keyword>occurrence of adverse events</keyword>
  <keyword>insulin secretion and sensitivity</keyword>
  <keyword>prevention</keyword>
  <keyword>abnormal glucose metabolism</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>drug intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
